Ambu A/S

Latest Results (23.05.2024):

Revenue Growth

In the second quarter of the 2023/24 financial year, Ambu A/S reported a significant increase in revenue. The company achieved an organic revenue growth of 15.5%, amounting to DKK 1,367 million. This growth was notably driven by a strong performance in the Endoscopy Solutions sector, which saw a 22.3% increase in revenue.

EBIT Improvement

Ambu A/S demonstrated a robust improvement in earnings before interest and taxes (EBIT) during the second quarter. The EBIT before special items reached DKK 194 million, translating to an EBIT margin of 14.2%. This represents a substantial improvement from the previous year's margin of 3.9%, reflecting effective cost management and operational efficiency.

Free Cash Flow Increase

The company also saw a significant improvement in its free cash flow. For the quarter, Ambu A/S reported a free cash flow before acquisitions of DKK 128 million, a notable increase from DKK 21 million in the same quarter of the previous year. This improvement underscores the company's enhanced liquidity and financial health.

Outlook for 2023/24

Following the strong performance in the first half of the year, Ambu A/S has raised its financial outlook for the full year 2023/24. The company now expects an organic revenue growth of 10-12% and an EBIT margin before special items of 10-12%. Additionally, the forecast for free cash flow has been increased to DKK +370 million.

Strategic Developments

Ambu A/S continues to strengthen its market position with strategic regulatory approvals and product launches. Notably, the company received FDA clearance for its aScope™ Duodeno 2 and aBox™ 2, enhancing its gastroenterology offerings. These developments are expected to support sustained growth and market penetration in North America and other regions.